CRISPR 制药
CRSP
49.25
-2.27
-4.41%
CRISPR 制药
US · CRSP
#2057 按市值排名
上市于 2016
49.25
-2.27
-4.41%
实时 - 追踪5344个代码 - 心跳于554秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了3.1个百分点。
机构持股
- 机构持股比例
- 78.76% -3.06pp
- 机构数量
- 604 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund58.11%
Hedge Fund6.83%
VC/PE Fund6.70%
Public Company2.95%
Private Company1.92%
Government Pension Fund1.51%
Individual/Insider0.45%
Sovereign Wealth Fund0.30%
Family Office/Trust0.28%
Other20.94%
主要股东 截至 2026-06-30
ARK Investment Management LLC
9.78% · 9.46M 股
BlackRock
8.63% · 8.35M 股
Capital Research
6.43% · 6.22M 股
Orbis Investment Management Limited
5.64% · 5.45M 股
State Street Global Advisors
4.47% · 4.32M 股
GSK Equity Investments, Limited
3.33% · 3.22M 股
Geode Capital Management, LLC
2.60% · 2.51M 股
T. Rowe Price Group, Inc.
2.26% · 2.18M 股
SR One Capital Management, LP
2.11% · 2.04M 股
Two Sigma Investments, LP
2.06% · 1.99M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 34次买入 · 16次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Samarth Kulkarni | Chairperson & CEO | 0.26% |
| James Kasinger | General Counsel | 0.10% |
| Douglas Treco | Lead Independent Director | 0.02% |
| Naimish Patel | Chief Medical Officer | 0.02% |
| Ali Behbahani | Independent Director | 0.02% |
| Raju Prasad | Chief Financial Officer | 0.02% |
| John Greene | Independent Director | 0.01% |
| Briggs Duncan W. Morrison | Independent Director | 0.01% |
| Katherine High | Independent Director | -- |
| Simeon George | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-21 | James Kasinger | General Counsel | Derivative Exercise and Sale | -10,400 | $13.62–60.24 |
| 2026-09-16 | Ali Behbahani | Independent Director | Derivative Exercise and Sale | -13,679 | $14.00–57.09 |
| 2026-09-16 | Ali Behbahani | Independent Director | Derivative Exercise and Retained | +16,321 | $14.00 |
| 2026-08-06 | Raju Prasad | Chief Financial Officer | Other Disposition | -750 | -- |
| 2026-06-04 | Douglas Treco | Lead Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | Katherine High | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | Briggs Duncan W. Morrison | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | Simeon George | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | Christian Rommel | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | Maria Fardis | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | Sandesh Mahatme | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | John Greene | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | Harold Fleming | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-06-04 | Ali Behbahani | Independent Director | Other Derivative Acquisition | +13,000 | $51.84 |
| 2026-05-28 | Raju Prasad | Chief Financial Officer | Other Derivative Acquisition | +19,500 | -- |
| 2026-05-28 | Naimish Patel | Chief Medical Officer | Derivative Exercise and Sale | -3,786 | $55.62 |
| 2026-05-28 | Naimish Patel | Chief Medical Officer | Other Derivative Acquisition | +22,000 | -- |
| 2026-05-28 | James Kasinger | General Counsel | Other Derivative Acquisition | +17,000 | -- |
| 2026-05-27 | Naimish Patel | Chief Medical Officer | Derivative Exercise and Retained | +6,214 | -- |
| 2026-03-22 | Samarth Kulkarni | Chairperson & CEO | Derivative Exercise and Sale | -10,020 | $46.78 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:15 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
CRISPR 制药 讨论区 0 条评论